FDA orders GLP-1 weight-loss drugs to add warning about rare eye condition
The US regulator has told manufacturers to update labels on GLP‑1 medications to note a possible link to a rare optic nerve condition that can cause sudden vision loss, according to reports.

The US Food and Drug Administration has required makers of GLP‑1 medicines used for weight loss to add warnings about a rare eye condition that can cause sudden and permanent vision loss, according to reporting from the BBC and the Guardian.
According to the BBC, the change affects well‑known injectable treatments used to help patients lose weight, with manufacturers instructed to include information about the risk on product labelling. The Guardian said the move applies across the class of GLP‑1 drugs and named several widely prescribed products as examples.
The condition named
The Guardian identified the condition as nonarteritic anterior ischaemic optic neuropathy, commonly shortened to NAION, and reported the FDA is requiring information about its potential association with GLP‑1 therapies to be added to warnings. The BBC also noted the regulator described the eye problem under the NAION name.
What the reports say and what is not yet clear
Both outlets reported the FDA action but did not present new data quantifying the risk. The Guardian listed specific brand examples affected by the labelling requirement; the BBC highlighted the broader instruction to drugmakers. Neither report claimed independent confirmation of the frequency of the condition in people taking these medicines.
Health professionals and patients should consult prescribing information and clinicians for individual guidance, and watch for further details from the FDA and manufacturers as the labels are updated, the reports said.
Sources
This story was written from reports by these outlets. Read the originals:



